Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
J Cachexia Sarcopenia Muscle. 2023 Dec;14(6):2768-2778. doi: 10.1002/jcsm.13353. Epub 2023 Oct 30.
Low skeletal muscle mass (myopenia) is common in cancer populations and is associated with functional decline and mortality, but prior oncology studies did not assess total body skeletal muscle mass. Instead, they measured surrogates such as cross-sectional area (CSA) of skeletal muscle at L3 from computed tomography (CT) or appendicular lean mass (ALM) from dual-energy X-ray absorptiometry (DXA). D3-creatine (D3Cr) dilution is a non-invasive method to assess total body skeletal muscle mass, which has been examined in a variety of populations but not in cancer. To compare the associations of D3Cr muscle mass, CT CSA, and DXA ALM with myopenia and physical function, we conducted a cross-sectional study among 119 patients with colon cancer (2018-2022).
For each technique (D3Cr, CT and DXA), myopenia was defined as the lowest sex-specific quartile of its measurement. Physical function was measured by the short physical performance battery and grip strength. We calculated Pearson correlations (r) among three techniques, computed Cohen's kappa coefficients (κ) to assess the agreement of myopenia, and estimated Pearson correlations (r) of three techniques with physical function. All analyses were sex-specific.
Sixty-one (51.3%) participants were male, the mean (standard deviation) age was 56.6 (12.9) years, and most (68.9%) had high physical function (short physical performance battery: ≥11 points). Correlations and myopenia agreement among three techniques were greater in men than women; for example, regarding D3Cr muscle mass versus CT CSA, r was 0.73 (P < 0.001) for men versus 0.45 (P < 0.001) for women, and κ was 0.82 (95% CI: 0.65, 0.99) for men versus 0.24 (95% CI: -0.08, 0.52) for women. Among men, higher D3Cr muscle mass was significantly correlated with faster gait speed (r = 0.43, P < 0.01) and stronger grip strength (r = 0.32, P < 0.05); similar correlations were observed for CT CSA and DXA ALM. However, among women, no measure of muscle or lean mass was significantly associated with physical function.
This is the first study using D3-creatine dilution method to assess muscle mass in a cancer population. Regardless of the techniques used for muscle or lean mass assessment, we observed stronger correlations, greater myopenia agreement, and more significant associations with physical function in men with colon cancer than women. D3Cr, CT and DXA are not interchangeable methods for assessing myopenia and physical function, especially in women with colon cancer. Future studies should consider relative advantages of these techniques and examine the D3-creatine dilution method in other cancer types.
低骨骼肌量(肌少症)在癌症人群中很常见,与功能下降和死亡率有关,但之前的肿瘤学研究并未评估全身骨骼肌量。相反,他们测量了来自 CT 的骨骼肌横截面积(CSA)或来自双能 X 射线吸收法(DXA)的四肢瘦体重(ALM)等替代指标。D3-肌酸(D3Cr)稀释是一种评估全身骨骼肌量的非侵入性方法,已在多种人群中进行了研究,但在癌症患者中尚未进行研究。为了比较 D3Cr 肌肉量、CT CSA 和 DXA ALM 与肌少症和身体功能的相关性,我们对 119 例结肠癌患者(2018-2022 年)进行了横断面研究。
对于每种技术(D3Cr、CT 和 DXA),肌少症定义为其测量的最低性别特异性四分位数。身体功能通过短体适能电池和握力来衡量。我们计算了三种技术之间的皮尔逊相关系数(r),计算了肌少症的科恩氏κ系数(κ)以评估其一致性,并估计了三种技术与身体功能的皮尔逊相关系数(r)。所有分析均按性别进行。
61 名(51.3%)参与者为男性,平均(标准差)年龄为 56.6(12.9)岁,大多数(68.9%)具有较高的身体功能(短体适能电池:≥11 分)。三种技术之间的相关性和肌少症一致性在男性中均大于女性;例如,关于 D3Cr 肌肉量与 CT CSA,男性的 r 为 0.73(P<0.001),女性的 r 为 0.45(P<0.001),男性的 κ 为 0.82(95%CI:0.65,0.99),女性的 κ 为 0.24(95%CI:-0.08,0.52)。在男性中,较高的 D3Cr 肌肉量与较快的步态速度(r=0.43,P<0.01)和较强的握力(r=0.32,P<0.05)呈显著相关;CT CSA 和 DXA ALM 也观察到类似的相关性。然而,在女性中,没有任何肌肉或瘦体重指标与身体功能显著相关。
这是第一项使用 D3-肌酸稀释法评估癌症人群肌肉量的研究。无论用于肌肉或瘦体重评估的技术如何,我们在结肠癌男性中观察到更强的相关性、更大的肌少症一致性以及与身体功能的更显著相关性,而在女性中则没有。D3Cr、CT 和 DXA 不是评估肌少症和身体功能的可互换方法,尤其是在结肠癌女性中。未来的研究应考虑这些技术的相对优势,并在其他癌症类型中研究 D3-肌酸稀释法。